Molecular pathogenesis of multiple myeloma and its premalignant precursor.

Multiple myeloma is a monoclonal tumor of plasma cells, and its development is preceded by a premalignant tumor with which it shares genetic abnormalities, including universal dysregulation of the cyclin D/retinoblastoma (cyclin D/RB) pathway. A complex interaction with the BM microenvironment, characterized by activation of osteoclasts and suppression of osteoblasts, leads to lytic bone disease. Intratumor genetic heterogeneity, which occurs in addition to intertumor heterogeneity, contributes to the rapid emergence of drug resistance in high-risk disease. Despite recent therapeutic advances, which have doubled the median survival time, myeloma continues to be a mostly incurable disease. Here we review the current understanding of myeloma pathogenesis and insight into new therapeutic strategies provided by animal models and genetic screens.

[1]  R. Noelle,et al.  The immortality of humoral immunity , 2010, Immunological reviews.

[2]  H. Johnsen,et al.  Identification of translocation products but not K-RAS mutations in memory B cells from patients with multiple myeloma , 2010, Haematologica.

[3]  J. Keats,et al.  Classical and/or alternative NF-kappaB pathway activation in multiple myeloma. , 2010, Blood.

[4]  Fiona M Ross,et al.  Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. , 2011, Blood.

[5]  L. Bruhn,et al.  Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. , 2007, Cancer cell.

[6]  C. Croce,et al.  MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis , 2008, Proceedings of the National Academy of Sciences.

[7]  T. Soussi,et al.  Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma , 2010, Haematologica.

[8]  Hermann Einsele,et al.  Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival. , 2011, Blood.

[9]  G. Mulligan,et al.  Clinical and Biological Implications of MYC Activation: A common difference between MGUS and newly diagnosed multiple myeloma , 2011, Leukemia.

[10]  L. Kovarova,et al.  Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders , 2010, British journal of haematology.

[11]  R. Bataille,et al.  Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myélome and the Groupe Français de Cytogénétique Hématologique. , 2001, Blood.

[12]  F. Zhan,et al.  Paradoxical expression of INK4c in proliferative multiple myeloma tumors: bi-allelic deletion vs increased expression , 2006, Cell Division.

[13]  Trevor J Pugh,et al.  Initial genome sequencing and analysis of multiple myeloma , 2011, Nature.

[14]  P. L. Bergsagel,et al.  AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. , 2008, Cancer cell.

[15]  C. Hart,et al.  Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug. , 2010, Blood.

[16]  G. Morgan,et al.  Mapping of Chromosome 1p Deletions in Myeloma Identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as Being Genes in Regions Associated with Adverse Survival , 2011, Clinical Cancer Research.

[17]  R. Hayes,et al.  Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. , 2009, Blood.

[18]  G. Roodman,et al.  Pathophysiology of myeloma bone disease. , 2007, Best practice & research. Clinical haematology.

[19]  P. Moreau,et al.  Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Axel Benner,et al.  Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma , 2011, Haematologica.

[21]  Kenneth C. Anderson,et al.  Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets , 2007, Nature Reviews Cancer.

[22]  L. Staudt,et al.  Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. , 2004, Cancer cell.

[23]  P. L. Bergsagel,et al.  Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. , 2012, Blood.

[24]  R. Bataille,et al.  The peripheral CD138+ population but not the CD138− population contains myeloma clonogenic cells in plasma cell leukaemia patients , 2012, British journal of haematology.

[25]  N. Munshi,et al.  Latest advances and current challenges in the treatment of multiple myeloma , 2012, Nature Reviews Clinical Oncology.

[26]  D. Hose,et al.  Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. , 2012, Blood.

[27]  Huey-Jen Lin,et al.  Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. , 2010, Cancer cell.

[28]  R. Young,et al.  BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.

[29]  A. Órfão,et al.  New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. , 2007, Blood.

[30]  K. Yata,et al.  The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells , 2004, Leukemia.

[31]  G. Morgan,et al.  A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. , 2010, Blood.

[32]  P. L. Bergsagel,et al.  Molecular pathogenesis and a consequent classification of multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  B. Barlogie,et al.  International Myeloma Working Group molecular classification of multiple myeloma: spotlight review , 2009, Leukemia.

[34]  L. Staudt,et al.  Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. , 2007, Cancer cell.

[35]  B. Barlogie,et al.  Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors , 2008, Genes, chromosomes & cancer.

[36]  G. Morgan,et al.  Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results , 2012, Haematologica.

[37]  H. Drexler,et al.  Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia. , 2000, Leukemia research.

[38]  R. Fonseca,et al.  Clinical and biological significance of RAS mutations in multiple myeloma , 2008, Leukemia.

[39]  A. Sweet-Cordero,et al.  Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon , 2008, Nature Genetics.

[40]  T. Therneau,et al.  Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study , 2010, The Lancet.

[41]  R. Kyle,et al.  Myeloma : biology and management , 1995 .

[42]  W. Kuehl,et al.  Ectopic expression of wild-type FGFR3 cooperates with MYC to accelerate development of B-cell lineage neoplasms , 2010, Leukemia.

[43]  F. Prósper,et al.  Smoldering Multiple Myeloma (SMM) at High-Risk of Progression to Symptomatic Disease: A Phase III, Randomized, Multicenter Trial Based On Lenalidomide-Dexamethasone (Len-Dex) as Induction Therapy Followed by Maintenance Therapy with Len Alone Vs No Treatment , 2010 .

[44]  Terry M Therneau,et al.  Prevalence of monoclonal gammopathy of undetermined significance. , 2006, The New England journal of medicine.

[45]  M. Gordon.  Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma , 2009 .

[46]  Christian Wiesmann,et al.  Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. , 2009, The Journal of clinical investigation.

[47]  Bart Barlogie,et al.  Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. , 2005, Blood.

[48]  A. Palumbo,et al.  Multiple myeloma. , 2011, The New England journal of medicine.

[49]  P. L. Bergsagel,et al.  Characterization of MYC translocations in multiple myeloma cell lines. , 2008, Journal of the National Cancer Institute. Monographs.

[50]  Hong Chang,et al.  CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. , 2004, Blood.

[51]  G. Morgan,et al.  The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. , 2012, Blood.

[52]  T. Therneau,et al.  Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. , 2005, Blood.

[53]  J. Carpten,et al.  Clonal competition with alternating dominance in multiple myeloma. , 2012, Blood.

[54]  L. Staudt,et al.  IRF4 addiction in multiple myeloma , 2008, Nature.

[55]  N. Cross,et al.  Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context , 2009, Haematologica.

[56]  Liewei Wang,et al.  MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites , 2010, Nature.

[57]  G. Morgan,et al.  Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. , 2011, Blood.

[58]  G. Roodman.  Targeting the bone microenvironment in multiple myeloma , 2010, Journal of Bone and Mineral Metabolism.

[59]  P. Sonneveld,et al.  Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. , 2010, Blood.

[60]  J. Licht,et al.  The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. , 2008, Blood.

[61]  R. Bataille,et al.  Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. , 2001, Blood.

[62]  Cheng Li,et al.  Prognostic significance of copy-number alterations in multiple myeloma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  P. L. Bergsagel,et al.  Genetic aberrations and survival in plasma cell leukemia , 2008, Leukemia.

[64]  J. Miguel,et al.  Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. , 2010, The Lancet. Oncology.

[65]  G. Requirand,et al.  Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study , 2009, British Journal of Cancer.

[66]  J. Carpten,et al.  DNA methylation analysis determines the high frequency of genic hypomethylation and low frequency of hypermethylation events in plasma cell tumors. , 2010, Cancer research.

[67]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[68]  B. Barlogie,et al.  Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2 , 2008, British journal of haematology.

[69]  A. Zingone,et al.  Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma. , 2011, Seminars in hematology.

[70]  T. Therneau,et al.  Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. , 2008, Blood.

[71]  A. Chadli.  THE CANCER CELL , 1924, La Presse medicale.

[72]  B. Barlogie,et al.  Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management , 2010, Leukemia.

[73]  P. L. Bergsagel,et al.  Multiple myeloma: evolving genetic events and host interactions , 2002, Nature Reviews Cancer.

[74]  D. Hose,et al.  Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability. , 2008, Blood.

[75]  C. Huff,et al.  Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. , 2008, Cancer research.

[76]  R. Howard,et al.  A monoclonal gammopathy precedes multiple myeloma in most patients. , 2009, Blood.

[77]  John Crowley,et al.  The molecular classification of multiple myeloma. , 2006, Blood.

[78]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[79]  L. Staudt,et al.  The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. , 2011, Blood.

[80]  H. Johnsen,et al.  Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. , 2005, Blood.

[81]  R. Carrasco,et al.  Pathogenesis of myeloma. , 2011, Annual review of pathology.

[82]  C. Bastard,et al.  Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases , 1998, Leukemia.

[83]  S. Jagannath,et al.  Enhancement of clonogenicity of human multiple myeloma by dendritic cells , 2006, The Journal of experimental medicine.